NEONC Technologies Company

NEONC Technologies, Inc. (NTI) is an early-stage cancer biotechnology company focused initially on intranasal (delivery through the nose) inhalation and other non traditional delivery of a novel, highly purified form of monoterpenes (oils from fruits & plants), alone or with other chemotherapeutic (cancer treatment chemicals) agents. It will initially be used in clinical research for first line treatment of malignant brain cancer (gliomas) and other aggressive brain cancers, and later for the treatment of lung cancer.
NTI was incorporated in the State of Delaware in 2008. The Company has assembled a highly qualified management team and board of directors. NTI is developing several proprietary molecules for clinical research some of which have demonstrated significant activity (positive results) in laboratory tests; NTI is accordingly building a portfolio of intellectual property around this research. In addition, the Company has reached an agreement with a manufacturer of active pharmaceutical ingredients for development and production of proprietary monoterpenes.
Technology: Preventive Medicine
Industry: Precision Medicine
Headquarters: Woodland Hills
Founded Date: 2008
Employees Number: 1-10
Funding Status: Seed

Visit Website
Register and Claim Ownership